Sensitivity Analysis
Uncertainty is addressed in the model using probabilistic sensitivity analysis. Statistical distributions were assigned to key model parameters to examine second-order uncertainty in the estimation of the parameter. Uncertainty was propagated through the model using Monte Carlo simulation, drawing parameter values at random 500 times from the particular distributions.
Clinical Data
Transition probabilities for movement between NYHA classes of heart failure for the no treatment strategy were estimated from the published literature (Yao et al. 2008 , Ford et al. 2012 . Changes of NYHA classes of the ferric carboxymaltose group and the placebo group were derived from the FAIR-HF trial (odds ratio for improvement by one class, 2.40; 95% CI,1.55 to 3.71; P<0.001). Changes of NYHA classes for the alternative "oral treatment" is based on secondary endpoint results of the placebo arm of RCTs (range: 0.04 -0.08) (Ghali et al. 2008 , Van Veldhuisen et al. 2007 ).
Resource Use and Costs
Data on the resource use of the included iron deficiency and CHF was collected in two steps. First, the medical resources were derived by literature (e.g. clinical trials like FAIR-HF, cohort studies including patients with CHF, treatment guidelines etc.). In a second step this literature review was transferred to the Austrian setting. The following direct medical costs were included:
• NYHA costs: patients in NYHA II have about 14% increased costs compared with NYHA I, NYHA III by 48% and NYHA IV by 71%.
• Medication costs: dosage equivalents of FCM and oral treatments were calculated based on the Ganzoni formular.
• Outpatient costs: GP consultations and blood count • Inpatients costs: hospitalization due to iron deficiency Austrian costs were derived from a number of publicly available sources like the DRG catalogue (LKF), official price lists for the Austrian Health insurances funds and the Austrian official drug price list (Warenverzeichnis). When necessary, prices were adjusted to 2014 prices using the consumer price index. 
Methods
We developed a Cost-Utility-Model to simulate disease progression in CHF patients using different strategies of iron deficiency management. Markov modelling techniques were used to estimate disease progression, based on health states, defined by NYHA classes and death. Monte Carlo simulation accounted for uncertainty. The model includes 5 states and monthly transitions. Probabilities were derived from clinical and epidemiological studies. The cohort definition was adapted from the FAIR-HF study. Direct costs (NYHA, inpatient, outpatient and iron treatment costs) from published sources were used and expressed in Euro (2014) from the payer's perspective. QALYs and total costs were projected over a 4-year time horizon and discounted at 5% p.a.
Source: own developed The analysis shows that iron deficiency therapy leads to reduced NYHA and hospitalization costs. Iron treatment costs are partly offset.
Decision model

Model description:
A simulated cohort of 1,000 patients aged 67 entered the Model. The breakdown of NYHA classes of the starting cohort represents the Austrian distribution (calculated based on Klip et al. 2013 and Klip et al. 2014 
